Administration of the anti-VLA4 monoclonal antibody natalizumab resulted in a significant increase of CD45 proportions and nearly significant rise in absolute counts of the nonclassical monocyte subset ( Figure 8 ).
← all excerpts
Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis.
1
—
—